IMMUNITYBIO INC

Insider buying at ImmunityBio signals leadership confidence ahead of FDA and market milestones for its ANKTIVA platform—potential upside despite current low valuation.

Insider sales at ImmunityBio signal liquidity moves, not distress—track this biotech’s pipeline, milestones, and investor sentiment for informed decisions.

Insider sales of ImmunityBio’s shares show routine portfolio shifts, not panic—backed by strong Anktiva data, regulatory approvals, and a 233% projected sales jump.

Insider buying signals optimism for ImmunityBio—executives buy shares and sell at highs as Anktiva gains traction, boosting confidence in the company’s growth and regulatory future.

ImmunityBio insider moves: CEO Patrick Soon‑Shiong buys 274K RSUs and sells 118K shares at $6.93, hinting at short‑term liquidity needs and confidence ahead of ASCO data.

Insider buying at ImmunityBio signals executive confidence ahead of ASCO data releases, highlighting potential upside despite RSU sales.

Insider trading at ImmunityBio: director Simon Barry sells 151k shares via Rule 10b5‑1, while executive Selecky trades amid growing social‑media buzz and 52‑week highs.